Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Mirikizumab (LY3074828) Coadministered with Hyaluronidase in Healthy Subjects
NCT03220126Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of mirikizumab in ulcerative colitis (UC), Crohn's disease and psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration versus Time Curve. Started Jul 2017; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's diseasepsoriasis
Beyond the preview
Go deeper on NCT03220126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220126.